Parnell Pharmaceuticals Holdings Ltd
OTC:PARNF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (0.1), the stock would be worth $0.09 (9% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.1 | $0.08 |
0%
|
| 3-Year Average | 0.1 | $0.09 |
+9%
|
| 5-Year Average | 0.1 | $0.09 |
+9%
|
| Industry Average | 18 | $11.71 |
+14 532%
|
| Country Average | 4.1 | $2.66 |
+3 221%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$1.4m
|
/ |
Jul 2016
AU$16.5m
|
= |
|
|
$1.4m
|
/ |
Dec 2016
AU$23.6m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Parnell Pharmaceuticals Holdings Ltd
OTC:PARNF
|
1.4m USD | 0.1 | -0.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 12.7 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 5.7 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 4.9 | 27.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 4.9 | 19.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 4.2 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 3.8 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 2.4 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 2.4 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.7 |
| Median | 4.1 |
| 70th Percentile | 11.8 |
| Max | 1 679 509.2 |
Other Multiples
Parnell Pharmaceuticals Holdings Ltd
Glance View
Parnell Pharmaceuticals Holdings Ltd. operates as a veterinary pharmaceutical company. The company is headquartered in Alexandria, New South Wales. The company went IPO on 2014-06-18. The firm is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets. The firm operates through four segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World and Manufacturing Operations. The company augments its pharmaceutical products with its FETCH and mySYNCH software platforms. The company offers disease-modifying product, Zydax, for the treatment of osteoarthritis (OA). Its reproductive hormone products include estroPLAN and GONAbreed. The company has a nutraceutical product, Glyde. The company also markets a non-steroidal anti-inflammatory drug (NSAID), called Tergive. The company is developing a pipeline of clinical drug candidates, such as PAR 121, PAR 122, PAR 101, PAR 081 and PAR 061.
